title: Ð Ð¾Ð»Ñ ÐÐÐÐÐ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² Ð² ÑÐ¾ÑÐ¼Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ð¸ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸ÑÐ¾ÑÐ¼Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð² 4-Ð°Ð¼Ð¸Ð½Ð¾Ð¿Ð¸ÑÐ¸Ð´Ð¸Ð½Ð¾Ð²Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»Ð¸ Ð½Ð° Ð¿ÐµÑÐµÐ¶Ð¸Ð²Ð°ÑÑÐ¸Ñ ÑÑÐµÐ·Ð°Ñ Ð¼Ð¾Ð·Ð³Ð° ÐºÑÑÑÑ
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: The role of GABAB receptors in formation of epileptiform activity in 4-aminopyridine model on acute rat`s brain slices
Creators: name: ÐÐ¾Ð»ÑÐºÐ¾Ð²Ð°, ÐÐ»ÐµÐºÑÐ°Ð½Ð´ÑÐ°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: Ð²Ð¸ÑÐ¾ÑÐ½Ð°Ñ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸Ñ
4-Ð°Ð¼Ð¸Ð½Ð¾Ð¿Ð¸ÑÐ¸Ð´Ð¸Ð½Ð¾Ð²Ð°Ñ Ð¼Ð¾Ð´ÐµÐ»Ñ Ð²Ð¸ÑÐ¾ÑÐ½Ð¾Ð¹ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸Ð¸
ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸ÑÐ¾ÑÐ¼Ð½Ð°Ñ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ
Ð¿ÑÐµ- Ð¸ Ð¿Ð¾ÑÑÑÐ¸Ð½Ð°Ð¿ÑÐ¸ÑÐµÑÐºÐ¸Ðµ ÐÐÐÐÐ ÑÐµÑÐµÐ¿ÑÐ¾ÑÑ
ÑÐ½ÑÐ¾ÑÐ¸Ð½Ð°Ð»ÑÐ½Ð°Ñ ÐºÐ¾ÑÐ°
Ð¿ÐµÑÐµÐ¶Ð¸Ð²Ð°ÑÑÐ¸Ðµ ÑÑÐµÐ·Ñ Ð¼Ð¾Ð·Ð³Ð° ÐºÑÑÑÑ
temporal lobe epilepsy
4-aminopyridine model of epilepsy
epileptiform activity
pre- and postsynaptic GABAB receptors
entorhinal cortex
acute rat`s brain slices

description: Ð Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÐµ Ð¾ÑÐµÐ½Ð¸Ð²Ð°Ð»Ð¾ÑÑ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ ÐÐÐÐÐ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² Ð½Ð° Ð¿ÑÐ¾ÑÐµÐºÐ°Ð½Ð¸Ðµ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸ÑÐ¾ÑÐ¼Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð² 4-Ð°Ð¼Ð¸Ð½Ð¾Ð¿Ð¸ÑÐ¸Ð´Ð¸Ð½Ð¾Ð²Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»Ð¸ in vitro. ÐÐ»Ñ Ð´Ð¾ÑÑÐ¸Ð¶ÐµÐ½Ð¸Ñ Ð¿Ð¾ÑÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾Ð¹ ÑÐµÐ»Ð¸ Ð±ÑÐ» Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½ ÑÑÐ´ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ¾Ð²: ÑÐµÐ³Ð¸ÑÑÑÐ°ÑÐ¸Ñ ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸ÑÐ¾ÑÐ¼Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸, Ð°Ð½Ð°Ð»Ð¸Ð· Ð¿Ð°ÑÐ½Ð¾Ð³Ð¾ Ð¾ÑÐ½Ð¾ÑÐµÐ½Ð¸Ñ Ð²ÑÐ·Ð²Ð°Ð½Ð½ÑÑ Ð²Ð¾Ð·Ð±ÑÐ¶Ð´Ð°ÑÑÐ¸Ñ Ð¿Ð¾ÑÑÑÐ¸Ð½Ð°Ð¿ÑÐ¸ÑÐµÑÐºÐ¸Ñ ÑÐ¾ÐºÐ¾Ð² (ÐÐÐ¡Ð¢), Ð¸ Ð¼Ð¸Ð½Ð¸Ð°ÑÑÑÐ½ÑÑ ÑÐ¾Ð±ÑÑÐ¸Ð¹. ÐÑÐ»Ð¾ Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð¾, ÑÑÐ¾ Ð°ÐºÑÐ¸Ð²Ð°ÑÐ¸Ñ ÐÐÐÐB ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð² (ÐÐÐÐÐ-Ð ) Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÐµÑ Ð²ÑÑÐ°Ð¶ÐµÐ½Ð½Ð¾Ðµ Ð¿ÑÐ¾ÑÐ¸Ð²Ð¾ÑÐ¿Ð¸Ð»ÐµÐ¿ÑÐ¸ÑÐµÑÐºÐ¾Ðµ Ð´ÐµÐ¹ÑÑÐ²Ð¸Ðµ Ð² 4-Ð°Ð¼Ð¸Ð½Ð¾Ð¿Ð¸ÑÐ¸Ð´Ð¸Ð½Ð¾Ð²Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»Ð¸ in vitro, ÑÐ½Ð¸Ð¶Ð°Ñ Ð´Ð»Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÑ Ð¸ ÑÐ°ÑÑÐ¾ÑÑ Ð¸ÐºÑÐ°Ð»ÑÐ½ÑÑ ÑÐ°Ð·ÑÑÐ´Ð¾Ð². ÐÐ³Ð¾Ð½Ð¸ÑÑ ÐÐÐÐÐ-Ð  SKF97541 Ð²ÑÐ·ÑÐ²Ð°Ð» ÑÐ¼ÐµÐ½ÑÑÐµÐ½Ð¸Ðµ Ð°Ð¼Ð¿Ð»Ð¸ÑÑÐ´Ñ Ð¿Ð¾ÑÑÑÐ¸Ð½Ð°Ð¿ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ²ÐµÑÐ¾Ð² Ð¸ ÑÐ²ÐµÐ»Ð¸ÑÐµÐ½Ð¸Ðµ Ð·Ð½Ð°ÑÐµÐ½Ð¸Ñ ÐºÐ¾ÑÑÑÐ¸ÑÐ¸ÐµÐ½ÑÐ° Ð¿Ð°ÑÐ½ÑÑ Ð¸Ð¼Ð¿ÑÐ»ÑÑÐ¾Ð², ÑÑÐ¾ ÑÐ²Ð¸Ð´ÐµÑÐµÐ»ÑÑÑÐ²ÑÐµÑ Ð¾ ÐµÐ³Ð¾ Ð·Ð½Ð°ÑÐ¸ÑÐµÐ»ÑÐ½Ð¾Ð¼ Ð²Ð»Ð¸ÑÐ½Ð¸Ð¸ Ð½Ð° Ð¿ÑÐµÑÐ¸Ð½Ð°Ð¿ÑÐ¸ÑÐµÑÐºÐ¸-Ð»Ð¾ÐºÐ°Ð»Ð¸Ð·Ð¾Ð²Ð°Ð½Ð½ÑÐµ ÑÐµÑÐµÐ¿ÑÐ¾ÑÑ. ÐÑÐ¸ ÑÑÐ¾Ð¼ ÑÐµÑÑ Ñ Ð¿Ð°ÑÐ½ÑÐ¼Ð¸ Ð¸Ð¼Ð¿ÑÐ»ÑÑÐ°Ð¼Ð¸ Ð½Ðµ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð» Ð´Ð¾ÑÑÐ¾Ð²ÐµÑÐ½ÑÑ Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð¸Ð¹ Ð² Ð°Ð¼Ð¿Ð»Ð¸ÑÑÐ´Ðµ Ð¾ÑÐ²ÐµÑÐ¾Ð² Ð¸ Ð¿Ð°ÑÐ½Ð¾Ð¼ Ð¾ÑÐ½Ð¾ÑÐµÐ½Ð¸Ð¸ Ð¿ÑÐ¸ Ð°Ð¿Ð¿Ð»Ð¸ÐºÐ°ÑÐ¸Ð¸ Ð±Ð»Ð¾ÐºÐ°ÑÐ¾ÑÐ° ÐÐÐÐÐ-Ð  CGP55845, ÑÑÐ¾ Ð³Ð¾Ð²Ð¾ÑÐ¸Ñ Ð¾ Ð½Ð¸Ð·ÐºÐ¾Ð¹ ÑÐ¾Ð½Ð¾Ð²Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð¿ÑÐµÑÐ¸Ð½Ð°Ð¿ÑÐ¸ÑÐµÑÐºÐ¸Ñ ÐÐÐÐÐ ÑÐµÑÐµÐ¿ÑÐ¾ÑÐ¾Ð². ÐÑÐ¸ Ð·Ð°Ð¿Ð¸ÑÐ¸ Ð¼Ð¸Ð½Ð¸Ð°ÑÑÑÐ½ÑÑ ÑÐ¾Ð±ÑÑÐ¸Ð¹ Ð½Ð¸ Ð°Ð³Ð¾Ð½Ð¸ÑÑ, Ð½Ð¸ Ð°Ð½ÑÐ°Ð³Ð¾Ð½Ð¸ÑÑ ÐÐÐÐÐ-Ð  Ð½Ðµ Ð¸Ð·Ð¼ÐµÐ½ÑÐ»Ð¸ Ð°Ð¼Ð¿Ð»Ð¸ÑÑÐ´Ñ, Ð²ÑÐµÐ¼Ñ Ð½Ð°ÑÐ°ÑÑÐ°Ð½Ð¸Ñ Ð¸ Ï ÑÐ¿Ð°Ð´Ð° Ð¼Ð¸Ð½Ð¸Ð°ÑÑÑÐ½ÑÑ Ð²Ð¾Ð·Ð±ÑÐ¶Ð´Ð°ÑÑÐ¸Ñ Ð¿Ð¾ÑÑÑÐ¸Ð½Ð°Ð¿ÑÐ¸ÑÐµÑÐºÐ¸Ñ ÑÐ¾ÐºÐ¾Ð² (Ð¼ÐÐÐ¡Ð¢). ÐÐ´Ð½Ð°ÐºÐ¾, CGP55845 ÑÐ²ÐµÐ»Ð¸ÑÐ¸Ð²Ð°Ð» ÑÐ°ÑÑÐ¾ÑÑ Ð²Ð¾Ð·Ð½Ð¸ÐºÐ½Ð¾Ð²ÐµÐ½Ð¸Ñ Ð¼ÐÐÐ¡Ð¢, Ð° SKF97541 ÑÐ¼ÐµÐ½ÑÑÐ°Ð» ÐµÑ.
description: In this work, the influence of GABAB receptors on the epileptiform activity in a 4-aminopyridine model of epilepsy in vitro was evaluated. To achieve this goal, several experiments were carried out: the registration of the epileptiform activity, paired pulse test, and the miniature events analysis. It was found that the activation of GABAB-receptors (GABAB-R) has a pronounced antiepileptic effect in the 4-aminopyridine model in vitro, reducing the duration and frequency of the ictal discharges. The GABAB-R agonist SKF97541 reduced the amplitude of the postsynaptic responses and increased the paired pulse ratio (PPR), which indicates its significant effect on the presynaptic GABAB receptors. In contrast, the application of the GABAB-R blocker CGP55845 did not affect the paired pulse ratio of the postsynaptic current amplitudes, which suggest the low levels of background activity of the presynaptic GABAB receptors. Miniature event analysis have shown that neither the GABAB-R agonist, nor the antagonist, changed the amplitude, rise time, or decay Ï of the miniature excitatory postsynaptic currents (mEPSC). However, CGP55845 increased the mEPSC frequency, while SKF97541 decreased it.